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1. Introduction 
 
1.1. The medulloblastoma 
Medulloblastoma is a primitive neuroectodermal tumour (PNET) arising in the 
posteria fossa (Kleihues and Sobin, 2000). It is the most frequent malignant 
brain tumor in childhood and accounts for approximately 20 percent of all 
primary tumors of the central nervous system in children and adolescents 
(Gjerris et al., 1998). The overall incidence rate is about 4.5 cases per million 
child years in the United Kingdom (Alston et al., 2003; Thorne et al., 1994) with 
similar incidence rates in other countries (Gjerris et al., 1998). The highest 
incidence is found in children between five and nine years of age (Alston et al., 
2003). Being a tumor of the posterior fossa, medulloblastoma often presents 
with ataxia and ophthalmologic signs and with symptoms of increased 
intracranial pressure, for example headaches and vomiting (Alston et al., 2003). 
Although centralized and evidence based treatment protocols have significantly 
improved the outcome of patients, still up to 30% of the children succumb to 
their disease within 5 years (Gilbertson, 2004). Currently, optimal treatment of 
medulloblastoma is a combination of maximal surgical resection, radiation 
therapy of both the tumor site and the craniospinal axis, and systemic 
chemotherapy (Taylor et al., 2003; Tarbell et al., 1991; Hughes et al., 1988; 
Evans et al., 1990; Kortmann et al., 2000; Tait et al., 1990). Major issues that 
challenge patients and physicians are the strong tendency of this cancer to 
metastasize along the cerebrospinal axis together with the fact that specific 
treatment options based on a tumor’s molecular background are still lacking. As 
a consequence, the necessarily aggressive treatment can lead to severe side 
effects including neurocognitive impairment, hearing loss, endocrine 
abnormalities and secondary cancers (Ris et al., 2001;  Rademaker-Lakhai et 
al., 2006; Packer et al., 2006; Laughton et al., 2008; Xu et al., 2004). In this 
context, it was essential to find that many familial and sporadic 
medulloblastomas are caused by a constitutive activation of either the Sonic 
hedgehog (Shh) or the Wnt/beta-catenin signaling pathway, and researchers 
are now trying to establish well-tolerated drugs that may inhibit these pathways 
(Crawford et al., 2007; Scales and de Sauvage, 2009). Apart from these two 
well-defined groups of medulloblastomas, more recent studies identified 
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additional groups that are distinguishable by array-based expression analysis 
(Kool et al., 2008; Cho et al.2011; Northcott et al. 2011, Figure 1).  
 
  
 
 
Figure 1 (Kool  et al., 2008): Kool and colleagues analyzed expression data of 62 
medulloblastoma samples and identified 5 distinct clusters of medulloblastomas, 
indicated  as A, B, C, D, and E. Schematic overview from Kool et al. 2008 with 
molecular, genetic, and clinical characteristics. 
 
 
Nevertheless, the diagnosis of medulloblastomas is still established according 
to the WHO (World Health Organization) criteria for the classification of central 
nervous system tumors, and these criteria are solely based on standard 
histology and immunohistochemistry (Louis et al., 2007). Interestingly, the 
desmoplastic and the rare extensively nodular variant of medulloblastomas, 
which typically show tumor nodules surrounded by very cell-dense areas 
containing reticulin fibers, largely overlap with tumors that are molecularly 
characterized by constitutive Shh signaling. All other molecular subgroups of 
medulloblastomas are mainly covered by histologically classic 
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medulloblastomas (Kool et al., 2008; Northcott et al. 2011, see Figure 1). 
Medulloblastomas of all groups display a neuronal protein expression signature 
and they are believed to arise from neuronal precursor cells. It is still unclear 
whether different subtypes of medulloblastomas may arise from different 
precursor populations, and indeed, recent advances have now proven in vivo 
that brainstem precursors may give rise to Wnt-associated medulloblastomas 
(Gibson et al. 2010), whereas granule neuron precursors are susceptible to 
develop Shh-associated medulloblastomas (Schüller et al., 2008). The 
mechanisms that control proliferation, differentiation and migration of these 
precursors have therefore been of particular interest to cancer researches, and 
the understanding of these mechanisms is considered crucial for the 
development of novel treatment strategies.  
 
 
1.2. The transcription factor BARHL1 
 
One of the transcription factors that regulate both the survival and the migration 
of cerebellar granule neuron precursors is the homeobox gene Barhl1 (Li et al., 
2004). Barhl1 is a mammalian homolog of the Drosophila BarH1 and BarH2 
genes, which encode homeodomain proteins that are primarily expressed in 
migrating neurons settling in specific domains within the diencephalon, 
rhombencephalon and spinal cord (Bulfone et al., 2000). Loss of Barhl1 function 
causes attenuated cerebellar foliation, defective radial migration and impaired 
survival of cerebellar granule neurons (Li et al., 2004). Interestingly, BARHL1 
was also identified to be expressed in medulloblastomas (Yokota et al., 1996), 
but its functional significance for tumor development and progression has not 
yet been investigated.  
 
 
1.3. Aim of this study 
 
The aim of this study is to define the role of BARHL1 in medulloblastoma. 
Several intentions are pursued: (1) BARHL1 expression levels in cerebella and 
in medulloblastomas of mice and humans are determined. (2) A mouse model 
for Shh-induced medulloblastoma is used to examine the function of Barhl1 in 
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vivo. (3) The prognostic significance of BARHL1 expression levels in human 
and murine medulloblastomas is investigated by evaluating the overall survival 
of mice and humans. 
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2. Material and Methods 
 
 
2.1. Patients and tumor samples  
 
A total of 44 surgical tumor samples from patients with medulloblastoma were 
analyzed. Patients included 25 males and 19 females. They were treated in the 
University Hospitals of Munich, Göttingen, Bremen, Hannover and Münster (all 
Germany). The majority of patients were enrolled in the German Society of 
Pediatric Hematology and Oncology multicenter treatment studies for pediatric 
malignant brain tumors (HIT). The average age was 11.0 years, and the median 
age was 7.0 years, ranging from 0.6 to 39.7 years. The follow up in survivors 
ranged from 1.1 to 145.2 months with an average of 55.8 months and a median 
of 46.0 months. 13 patients succumbed to their disease, and 31 were alive as of 
September 1, 2010. The study included 29 medulloblastomas of classic 
histology, 11 medulloblastomas of desmoplastic histology and 4 
medulloblastomas with extensive nodularity. An overview on clinical data and 
histology is given in Table 1. Tumor diagnosis was established by standard 
light-microscopic evaluation of H&E sections and silver stains. Diagnoses were 
made independently by at least two neuropathologists based on the criteria of 
the latest WHO brain tumor classification (Louis et al., 2007). For gene copy 
number analysis, tumor tissues obtained from six glioblastoma multiforme were 
included as controls. Autopsy material of normal cerebella was obtained from 
patients, who gave their informed consent. Patient age ranged between 18 and 
67 years for the adult cerebella and between 22 weeks of gestation and 6 
months for the developing cerebella. None of these patients died from a central 
nervous system disorder or showed neuropathological abnormalities on 
histological examination. All tissue samples were either immediately fixed in 
formaldehyde and embedded in paraffin or snap frozen and stored at -80°C until 
use. 
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Table 1: Summary of tumor pathology and clinical data in ex amined 
medulloblastoma cases. NED: no evidence of disease. DOD: death of disease. 
 
Sample 
number 
MB subtype Sex 
Age 
[years] 
Follow up 
[months] 
State 
Relative 
BARHL1 
mRNA 
expression 
1 classic f 0.6 12.7 DOD 37.87 
2 classic m 2.4 21.0 DOD 23.13 
3 classic f 3.6 21.1 DOD 5.48 
4 classic f 3.7 5.4 NED 133.63 
5 classic f 3.8 47.1 NED 9.02 
6 classic m 4.1 35.4 NED 0.01 
7 classic m 4.9 75.7 DOD 16.69 
8 classic m 5.4 135.6 NED 47.93 
9 classic f 5.5 28.3 DOD 26.14 
10 classic m 5.5 137.5 NED 60.78 
11 classic m 5.9 1.1 NED 44.54 
12 classic f 6.1 145.2 NED 1.92 
13 classic m 6.2 22.2 DOD 2.96 
14 classic m 6.7 33.4 NED 366.14 
15 classic m 7.0 113.2 NED 2.07 
16 classic m 7.0 142.8 NED 2.08 
17 classic m 7.9 24.1 DOD 0.52 
18 classic m 8.5 36.5 DOD 26.54 
19 classic m 8.8 8.8 NED 367.04 
20 classic m 9.3 50.3 NED 56.40 
21 classic m 9.9 79 NED 0.49 
22 classic m 10.6 23.7 NED 1.07 
23 classic m 16.5 18.3 NED 1.07 
24 classic m 22.3 35.3 NED 2.68 
25 classic f 23.6 80.8 NED 54.73 
26 classic f 25.5 133.7 NED 86.59 
27 classic f 29.3 19.5 NED 5.84 
28 classic m 37.5 4.8 DOD 35.06 
29 classic m 39.7 24.4 DOD 2.15 
30 desmoplastic f 1.6 66.9 NED 2.92 
31 desmoplastic f 2.2 128.0 NED 62.27 
32 desmoplastic m 2.5 7.0 DOD 0.08 
33 desmoplastic m 7.5 14.2 DOD 3.56 
34 desmoplastic m 10.0 101.4 NED 78.99 
35 desmoplastic f 14.3 62.7 DOD 778.79 
36 desmoplastic m 22.8 47.3 NED 8.26 
37 desmoplastic f 25.5 75.5 NED 0.46 
38 desmoplastic f 26.5 46.0 NED 54.33 
39 desmoplastic f 30.5 46.4 NED 4.72 
40 desmoplastic f 30.7 17.7 NED 12.91 
41 extensively nodular f 0.7 107.3 NED 0.15 
42 extensively nodular f 2.2 175.6 NED 3.27 
43 extensively nodular m 2.7 5.6 NED 1.97 
44 extensively nodular f 2.9 78.4 NED 0.18 
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2.2. Transgenic mice 
 
Barhl1-/- mice 
Barhl1-/- mice have been obtained from Dr. Shengguo Li and Prof. Dr. Mengqing 
Xiang (University of Medicine and Dentistry of New Jersey). To knock out 
Barhl1, the three Barhl1-coding exons were replaced with lacZ marker DNA and 
a PGK-Neo cassette flanked by two loxP sites (Li et al., 2002, see Figure 2). 
Primers for wild type Barhl1 were: Barhl1 WT Fw, 5’- 
GCTGAGTCCACGCTCAGAGAGCAG -3’; Barhl1 WT Rv, 5’- 
CTCAGAGTCTGATGAAGCGCTGCTG -3’ (Li et al., 2002). Barhl1 knockout 
was detected with the following primers: Barhl1 Fw, 5’- 
CCCATTCCTCCTGACACTC -3’; LacZ Rv, 5’- GACAGTATCGGCCT-CAGGAA 
-3’ (see Figure 2).  
 
 
Figure 2:  Schematic structure of the Barhl1 knockout allele generated by Li and 
colleagues. The three Barhl1-coding exons were replaced with lacZ marker DNA and a 
PGK-Neo cassette flanked by two loxP sites (grey boxes). The red bars represent the 
primers to detect the Barhl1 wild type genotype, the blue bars represent the primers to 
detect the Barhl1 knockout genotype. 
 
 
Math1-cre mice 
Math1-cre transgenic mice carry the bacteriophage P1 cre recombinase under 
control of a 1.4-kb upstream Math1 enhancer element (Heine and Rowitch, 
2009; Schüller et al., 2007; Matei et al., 2005). As a consequence, cre is 
produced specifically in cerebellar granule cell precursor cells (Schüller et al., 
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2007). Internal cre primers were used to detect the Math1-cre allele: cre Fw, 5′- 
TCCGGGCTGCCACGACCAA -3′; cre Rv 5′- GGCGCGGCAACACCATTTT -3′ 
(Heine and Rowitch, 2009).  
 
SmoM2Fl/Fl (Gt(ROSA)26Sortm1(Smo/EYFP)Amc/J mice 
SmoM2Fl/Fl (Gt(ROSA)26Sortm1(Smo/EYFP)Amc/J (Mao et al., 2006) mice were 
obtained from Jackson Laboratory (Bar Harbour, ME, USA). In these mice, a 
floxed neo/4xpA-SmoM2-YFP cassette was inserted into pROSA26PA (Srinivas 
et al., 2001; Mao et al., 2006, see Figure 3). SmoM2 itself contains a point 
mutation, defined as W539L, which leads to constitutive activation of 
Smoothened and consequently to a permanent activation of the Sonic 
hedgehog pathway (Xie et al., 1998). Primers used to detect SmoM2 and the 
wild type allele were as follows: SmoM2 Fw, 5’- AAGTTCATCTGCACCACCG -
3’; SmoM2 Rv, 5’- TCCTTGAAGAAGATGGTGCG -3’; Smo WT Fw, 5’- 
GGAGCGGGAGAAATGGATATG -3’; Smo WT Rv, 5’- 
CGTGATCTGCAACTCCAGTC -3’ (Jeong et al., 2004; Soriano, 1999). 
 
 
Figure 3: (A) Schematic structure of the SmoM2Fl/Fl (Gt(ROSA)26Sortm1(Smo/EYFP)Amc/J 
mouse model created by Mao and colleagues. A fused gene composed of SmoM2 and 
yellow fluorescent protein (YFP) was targeted into the Rosa26 locus.  Upstream, a 
polyadenylation stop sequence cassette (4x pA) was inserted to prevent expression of 
the mutant Smoothened. (B) If cre recombinase is present, the LoxP-flanked 
polyadenylation stop sequence is removed and the mutant Smoothened will be 
expressed leading to autonomous activation of the Sonic hedgehog pathway. 
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Barhl1-/- mice, Math1-cre mice and SmoM2Fl/Fl (Gt(ROSA)26Sortm1(Smo/EYFP)Amc/J 
mice were crossed to produce Math1-cre:SmoM2Fl/+, Barhl1+/-Math1-
cre:SmoM2Fl/+ and Barhl1-/-Math1-cre:SmoM2Fl/+ mice. To exclude influences of 
the genetic background, the mice were crossed in a manner that all examined 
genotypes (Math1-cre:SmoM2Fl/+, Barhl1+/-Math1-cre:SmoM2Fl/+ and Barhl1-/-
Math1-cre:SmoM2Fl/+ mice) were produced in one litter. Figure 4 shows a 
schematic overview of breeding. Genotyping for all mice was done by PCR 
analysis using genomic DNA from mouse tail biopsies. Each tail biopsy was 
lysed  for 2 hours at 55°C using 300 µl lysis buffe r (containing 100 mM Tris pH 
8.5, 5 mM EDTA pH 8.0, 0.2% SDS (filtered) and 200 mM NaCl) and 10 µl of 
Proteinase K. 300 µl of Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v; 
Invitrogen) was added and the sample was mixed for 5 minutes. Centrifugation 
at room temperature was done for 15 minutes with 13000 x g. The top layer was 
extracted (about 200 µl) and 50 µl of 3 M sodium acetate (pH 5.2) and 1 ml of 
cold 95% ethanol were added. After mixing, centrifugation was done at 4°C for 
10 minutes with 13000 x g. The liquid was discarded and the remaining pellet 
was washed with 800 µl 70% ethanol. After another centrifugation at 4°C for 10 
minutes with 13000 x g all liquid was removed and the pellet containing the 
DNA was dissolved in 100 µl DEPC water and stored at 4°C. Tumor-prone mice 
carrying both the Math1-cre and the SmoM2 allele (see Figure 4) were 
monitored twice daily for signs of neurological symptoms or general weakness.  
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Figure 4:  Principles of breeding 
 
 
2.3. DNA and RNA extraction, Real-time RT-PCR 
 
For DNA and RNA extraction paraffin-embedded tissues containing at least 
90% tumor material, as confirmed by H&E sections, were used. For snap-frozen 
tissues instantaneous sections were performed to assure a tumor fraction of at 
least 90%. DNA for real-time RT-PCR analysis was extracted from formalin-
fixed paraffin-embedded tissues using the QIAamp DNA FFPE Tissue Kit 
(Qiagen). Total RNA was extracted from snap-frozen tissues using TRIzol® 
reagent (Invitrogen). 20 - 30 10 µm slices of snap-frozen tissue were carefully 
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mixed with 750 µl Trizol and incubated at room temperature for 5 minutes. 150 
µl chloroform was added and the composite was mixed and incubated at room 
temperature for 3 minutes. Centrifugation was done at 4°C for 15 minutes with 
14000 x g. The top layer containing RNA and chloroform was extracted (about 
300 µl) and 375 µl isopropanol were added to precipitate the RNA. After mixing, 
centrifugation was done at 4°C for 10 minutes with 14000 x g. The liquid was 
discarded and the pellet was washed with 750 µl 75% ethanol. Another 
centrifugation was done at 4°C for 5 minutes with 7 500 x g. The ethanol was 
removed and the remaining RNA was dissolved in 24 µl DEPC water and stored 
at -80°C. Total RNA from paraffin-embedded tissues was obtained using the 
RNeasy FFPE Kit (Qiagen). Total RNA was treated with RNase-Free DNase 
(Promega). Therefore, 8 µl RNA (in DEPC water), 1 µl RQ1 RNase-Free DNase 
10x Reaction Buffer and 1 u/µg RNA of RQ1 RNase-Free DNase were mixed 
and incubated at 37°C for 30 minutes. Then, 1 µl of  DNase Stop solution was 
added to terminate the reaction. The mixture was incubated at 65°C for 10 
minutes to inactivate the DNase. Superscript II reverse transcriptase 
(Invitrogen) was used to run reverse transcription for human samples. Up to 4 
µg total RNA in up to 8 µl was used for the reaction. For each reaction 0.5 µl 
Oligo (dT)15 primers and 0.5 µl random hexamers (50 ng/µl) were mixed and 
added to the RNA. 1 µl of 10 mM dNTP mix was added. If less than 8 µl of RNA 
were used, the composite was filled to 10 µl with DEPC-treated water. The 
sample was incubated at 65°C for 5 minutes and then  cooled on ice for at least 
1 minute. 9 µl of reaction mixture (containing 2 µl 10X RT buffer, 4 µl 25 mM 
MgCl2, 2µl 0.1 M DTT and 1 µl RNaseOUT Recombinant Ribonuclease Inhibitor 
(all Invitrogen)) were added to each sample, the composite was mixed carefully 
and incubated at 25°C for 2 minutes. 1 µl (50 units ) of Superscript II reverse 
transcriptase (Invitrogen) were added to each sample. The mixture was 
incubated at 25°C for 5 minutes, at 42°C for 50 min utes and at 70°C for 15 
minutes. The samples were stored on ice. After adding 1 µl of RNase H 
(Invitrogen), the sample was incubated at 37°C for 20 minutes. Reverse 
transcription of mouse samples was performed using random hexamers and 
Transcriptor High Fidelity Reverse Transcriptase (Roche). Up to 4 µg total RNA 
were mixed with 1 µl anchored-oligo(dT)18 Primers (50 pmol/µl) and 1 µl 
Random Hexamer Primers (600 pmol/µl) and PCR-grade water was added to fill 
the sample volume to 11.4µl. The template-primer mixture was denaturated by 
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incubating for 10 minutes at 65°C. For each reactio n, 8.6 µl of RT mix 
(containing 4 µl 5x Transcriptor High Fideltiy Reverse Transcriptase Reaction 
Buffer, 0.5 µl Protector RNase Inhibitor 40 u/µl, 2 µl Deoxynucleotide Mix (10 
mM), 1 µl DTT and 1.1 µl Transcriptor High Fidelity Reverse Transcriptase (all 
Roche)) was added and the reagents were mixed carefully. The sample was 
incubated at 50°C for 30 minutes, at 85°C for 5 min utes and then placed on ice. 
For real-time quantitative reverse transcriptase (RT)–PCR, the LightCycler®480 
system (Roche), with 96 multiwell-plates, and the SYBR Green detection format 
was used. SYBR Green I is a DNA double-strand-specific dye that can be 
detected by its fluorescence when binding to the amplified PCR products. For 
each reaction, 5 µl of LightCycler®480 SYBR Green I Master Mix (containing 
FastStart Taq DNA Polymerase and DNA double-strand-specific SYBR Green I 
dye (Roche)), 1 µl of forward (Fw) Primer and 1 µl of reverse (Rv) Primer were 
added to 3 µl of cDNA. After incubation at 95°C for  5 minutes, 45 PCR Cycles 
were performed: 95°C for 10 seconds (Denaturation),  57-60°C for 10 seconds 
(Annealing according to Primers) and 72°C for 15 se conds (Elongation). After 
each Elongation step fluorescence of SYBR Green I was detected (real-time 
PCR). Relative quantification was done by normalizing the target gene with a 
housekeeper gene. Different reaction rounds were normalized by using a 
calibrator, a positive sample that was measured in every round. Beta-2-
microglobulin was used as a housekeeper, as it proved to be highly consistently 
expressed in medulloblastoma cells (data not shown). All analyses were done in 
triplicates. Primers were designed using the Primer3 software.  
Sequences of Primers are shown in table 2. 
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Table 2:  Primers used for real-time RT-PCR 
 
 
Primer name 
 
Sequence 
 
B2M (cDNA) Fw 
 
5’-TGTCTTTCAGCAAGGACTGG-3’ 
B2M (cDNA) Rv 5’-GATGCTGCTTACATGTAT CG-3’ 
BARHL1 (cDNA) Fw 5’-GAGCGGCAGAAGTACCTGAG-3’ 
BARHL1 (cDNA) Rv 5’-AGAAATAAGGCGACGGGAAC-3’ 
B2M (gDNA) Fw 5’-CAGTAAAGGAGTGGGGGATG-3’ 
B2M (gDNA) Rv 5’-TTGTGTTGAGGCAGGAAAAA-3’ 
BARHL1 (gDNA) Fw 5’-TTCCATTTTCATCCCATCGT-3’ 
BARHL1 (gDNA) Rv 5’- TCTTCCCTTTCCCTTCCTTC-3’ 
B2m Fw 5’-CCTGGTCTTTCTGGTGCTTG-3’ 
B2m Rv 5’-TATGTTCGG CTTCCCATTCT-3’ 
Barhl1 Fw 5’-CGCTCAACCTCACCGACA-3’ 
Barhl1 Rv 5’-AGAAATAAGGCGACGGGAAC-3’ 
 
 
For each set of primers postamplification melting curves were analyzed with the 
LightCycler®480 software, and agarose gel electrophoresis was performed to 
verify the presence of a single amplification product. Efficiency correction for 
each set of primers was done by creating a standard curve. Measured 
efficiencies are shown in table 3.   
 
Table 3:  Primer efficiencies for real-time RT-PCR 
 
 
Primer name 
 
Efficiency 
 
Annealing temperature 
 
B2M (cDNA) Primers 
 
2.119 
 
58°C 
BARHL1 (cDNA) Primers 2.002 60°C 
B2M (gDNA) Primers 2.007 57°C 
BARHL1 (gDNA) Primers 2.067 57°C 
B2m Primers 2.025 60°C 
Barhl1 Primers 1.919 60°C 
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The calibrator normalized relative ratio was calculated the following way: 
 
NR = E T 
[CpT (C) – CpT (S)] x EH
 [CpH (S) – CpH (C)] 
 
The abbreviation NR represents the normalized ratio, E stands for efficiency, T 
for target gene, H for housekeeper gene, C stands for calibrator, S for sample, 
and CpT and CpH are abbreviations for the cycle number at target and 
housekeeper detection threshold (crossing point), respectively. 
 
 
2.4. Histology, in situ hybridization and immunohis tochemistry 
 
For hematoxylin and eosin (H&E) stainings and for immunohistochemical 
procedures, brain and tumor tissue was fixed in 4% paraformaldehyde/PBS 
overnight at 4°C. Tissue for frozen sections was eq uilibrated in 20% 
glucose/PBS (pH 7.4) and embedded in OCT. 12 µm parasagittal sections were 
prepared on Superfrost plus slides (Fisher). Tissue for paraffin wax-embedded 
sections was dehydrated, embedded and sectioned at 5 µm according to 
standard protocols. Overall morphology was assessed by staining with H&E. All 
photomicrographs including those from immunohistochemical experiments were 
taken digitally using an Olympus Bx50 microscope in combination with the Color 
view Soft imaging system and Cell software (Olympus). In situ hybridization 
(ISH) was performed on frozen sections. RNA probe was synthesized by mixing 
13 µl DEPC treated water, 1 µl linearized template (1 µg/µl), 2 µl 10x 
transcription buffer (Roche), 2 µl DIG Label Mix (Roche) and 2 µl RNA 
polymerase (Roche, 20 u/µl). The composite was incubated at 37°C for 2 hours. 
0.5 µl of 0.5 M EDTA (pH 8), 100 µl DEPC-H2O, 10 µl 8 M LiCl, and 300 µl 
ethanol were added and the sample was incubated at -20°C for 2 hours. 
Centrifugation was done for 15 minutes at 13000 x g. The pellet was washed 
with 1 ml 70% DEPC ethanol. Another centrifugation was done for 10 minutes 
with 13000 x g. The fluid was removed and the pellet was resuspended at 37°C 
in 50 µl DEPC treated water. 1 µl RNA probe was mixed with 100 µl 
hybridization buffer (100 ml containing  50 ml Formamide (50%), 25 ml 20x SSC 
pH 4.5, 1 ml yeast tRNA (10 mg/ml), 10 mg Heparin (100 µg/ml), 1 ml 100x 
Denhardt’s, 100 µl Tween 20, 100 mg CHAPS (0.1%), 1 ml 0.5 M EDTA (5 mM) 
 19 
and 22 ml DEPC-H2O). Brain sections were washed with DEPC-PBS (1 ml 
DEPC in 1 l PBS), fixed with 4% PFA in PBS at room temperature for 15 
minutes and treated with 10 µg/ml proteinase K/PBS at room temperature for 10 
minutes. Brain sections were hybridized overnight with labeled RNA probes at 
65ºC, washed twice in 0.2x SSC pH 4.5, 0.1% Tween 20 at 65°C, washed twice 
in MBST buffer, pH 7.5, containing 100 mM maleic acid, 150 mM NaCl2, 2 mM 
levamisole and 0.1% Tween 20, blocked in MBST with 2% BM blocking agent 
(Roche) and 20% lamb serum, and incubated with alkaline phosphatase labeled 
anti-DIG antibodies (Roche, 1:2500 in 2% serum) for 2 hours. Sections were 
washed and color was visualized using BM purple (Roche). 
Immunohistochemistry was performed on frozen or formalin-fixed, paraffin-
embedded, rehydrated, 4 µm thick sections using the avidin–biotin–peroxidase 
complex (ABC) method on an automated system (BenchMark, Ventana). 
Primary antibodies against Synaptophysin (DAKO, 1:100), MAP2 (Sigma, 
1:40000), Cre (Covance, 1:1500), BARHL1 (Chemicon, 1:200), NeuN 
(Chemicon, 1:300), Zic (gift from Dr. R. Segal, 1:3000), OLIG2 (Chemicon, 
1:1000), Sox2 (Chemicon, 1:1000) and phosphorylated Histone H3 (Cell 
signaling, 1:200) were diluted in phosphate-buffered saline (PBS) and applied 
on sections for 30 minutes at 42°C. Cell nuclei wer e visualized by hematoxylin.  
 
 
2.5. Western blot analysis 
 
Proteins were extracted from frozen tumor samples. Lysis was performed on ice 
for 30 minutes in 500 µl of ice-cold lysis buffer containing 50 mmol/L Tris-HCl 
(pH 8), 120 mmol/L NaCl, 0.5% Nonidet P-40, 1 mmol/L phenylmethyl sulfonyl 
fluoride (Sigma), 100 U/ml aprotinin (Calbiochem), and 0.1 mol/L NaF. Debris 
was removed by centrifugation for 20 minutes at 12,000 x g and at 4°C. 
Proteins were separated by electrophoresis on 4 to 12% Bis-Tris gels (Nu-
PAGE, Invitrogen) and blotted onto nitrocellulose. To document equal loading of 
the gels, Ponceau staining of the membranes was performed. Blocking was 
performed with 10% nonfat dry milk (Bio-Rad, München, Germany) in Tris-
buffered saline containing 0.05% Tween 20 and 20% horse serum for 2 hours at 
room temperature. Filters were incubated with a Cleaved Caspase-3 (Asp175, 
Cell Signaling Technology) and a β-actin antibody (clone AC-15, Sigma) as 
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internal control according to the instructions of the manufacturers (Hartmann et 
al., 2005). Binding of the primary antibody was detected by a secondary 
antibody labeled with horseradish peroxidise (Amersham). The filters were 
developed using enhanced chemiluminescence detection reagents (Amersham, 
Buckinghamshire, UK).  
 
 
2.6. Statistical analysis 
 
All obtained results were analyzed using the Prism4 software (Graph Pad). 
Survival of patients and mice was analyzed using Kaplan-Meier survival curves 
and the Log-rank test was used to examine the significance of results. P-values 
<0.05 were considered significant. The unpaired t-test was applied to compare 
the means of two groups with assumed Gaussian distribution and equal 
variances. If variances were not equal, as confined by the F-test, or Gaussian 
distribution was not expected, the non parametric Mann-Whitney test for 
unpaired data was used to compare the medians of two groups. To compare 
protein expression patterns of Math1-cre:SmoM2Fl/+, Barhl1+/-Math1-
cre:SmoM2Fl/+ and Barhl1-/-Math1-cre:SmoM2Fl/+ mice, at least 3 animals were 
examined in each group and at least 500 tumor cells were counted in each 
animal. For pHH3 analysis 1000 tumor cells were counted. The respective 
histograms illustrate the mean with standard errors (error bars). Correlation of 
two paired data sets was done with Pearson correlation for Gaussian 
distributions or else with nonparametric Spearman correlation, with r as 
correlation coefficient. 
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3. Results 
 
3.1. BARHL1 expression in human medulloblastomas 
 
Barhl1 was found to have essential roles for cerebellar granule neuron 
precursors and for the overall development of the cerebellum (Li et al., 2004). 
Medulloblastomas derive, at least in part, from these precursor cells, and 
therefore, the purpose was to investigate whether human medulloblastomas 
express BARHL1 and how this would functionally be involved in tumorigenesis. 
In a first step, BARHL1 expression in a series of 19 normal tissues and 17 
different types of cancer was investigated. Serial analysis of gene expression 
(SAGE) analysis revealed that BARHL1 was highly expressed in the cerebellum 
and even stronger in the medulloblastoma, but only weakly in other types of 
brain cancer. Several types of normal tissues and tumors outside the central 
nervous system did not show any significant expression of BARHL1 (Figure 5). 
 
 
 
Figure 5: Expression of BARHL1 in different tissues indicating specificity of high 
expression in cerebellar tissue and medulloblastoma. Serial analysis of gene 
expression data for BARHL1 (SAGE tag: AGCCCGTGAC) is based on data extracted 
from the Cancer Genome Anatomy project (CGAP) as well as the Genomics institute of 
the Novartis Research Foundation (GNF) SymAtlas and was obtained from 
http://www.genecards.org/index.shtml. Filled diamonds=insignificant expression after 
thresholding and normalization. Empty diamonds=no data. 
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Next, real-time reverse transcriptase (RT)–PCR was used to confirm and 
extend the expression pattern of BARHL1 in human cerebellum and in 
medulloblastoma. As demonstrated in Figure 6, expression of BARHL1 was 
about 30-fold higher in the developing cerebellum (n=6) as compared to 
samples of adult cerebellum (n=8, p<0.001). Surgically removed 
medulloblastoma tissue samples (n=44) were characterized by a more 
heterogeneous expression pattern with many cases showing strong BARHL1 
expression (p=0.003, Figure 6). The median was 7.05 (range, 0.01-778.79) as 
compared to the median of adult cerebellum samples which was set 1 (Figure 6, 
Table 1).  
 
 
Figure 6:  Real-time RT-PCR of adult cerebella (n=8), developing cerebella (n=6) and 
human medulloblastoma tissue samples (n=44). BARHL1 expression was normalized 
to Beta-2-microglobulin (B2M) expression. BARHL1 expression was significantly 
upregulated in developing cerebella and in medulloblastomas as compared to adult 
cerebella (p<0.001 and p=0.003 respectively). Mean of expression in adult cerebella 
was set 1; dotted lines show mean±3*SD of expression in adult cerebella; solid lines 
represent median of each group. Two asterisks: p≤0.01, three asterisks: p≤0.001. 
 
 
Patient’s age and levels of BARHL1 expression did not show any significant 
correlation (r=0.127, p=0.411, Figure 7).  
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Figure 7: Relative BARHL1 expression and age distribution of medulloblastoma 
patients. BARHL1 overexpression was found in patients between 0.6 and 39.7 years of 
age. BARHL1 expression and age did not show any significant correlation (r=0.127, 
p=0.411). 
 
 
The series included 29 classic medulloblastomas and 11 desmoplastic 
medulloblastomas, but no significant difference with regard to the expression of 
BARHL1 in these two histological subtypes could be observed (p=0.952, Figure 
8).  
 
Figure 8:  Real-time RT-PCR analysis of BARHL1 expression in desmoplastic (n=11) 
and classic (n=29) medulloblastomas. BARHL1 overexpression (defined as >mean 
expression of normal adult cerebellum+3*SD, see dotted line) was found in both 
histological subtypes without statistically significant differences (p=0.952). Solid lines: 
median in each group. CI: confidence interval, n.s.: not significant. 
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To confirm the RNA expression data, immunohistochemistry on snap-frozen 
tissues expressing high or low levels of BARHL1 was performed. 
Medulloblastoma samples that were shown to highly express BARHL1 via real-
time RT-PCR and that were attributed to the high BARHL1 group (see Figure 
15), exhibited a strong nuclear staining for the transcription factor BARHL1, 
whereas medulloblastoma samples belonging to the low BARHL1 group (see 
Figure 15) did not or barely stain for BARHL1 (Figure 9 A and B).  
 
 
 
 
Figure 9: Immunohistochemistry for BARHL1. (A) Absence of staining for BARHL1 in 
medulloblastoma samples exhibiting low levels of BARHL1 mRNA. (B) Arrows point at 
strong nuclear staining of medulloblastoma cells in medulloblastoma samples that were 
shown to highly express BARHL1. Scale bar is 50 µm. 
 
 
Finally, quantitative real-time RT-PCR on genomic DNA from medulloblastoma 
samples (n=32) was used to exclude that genomic amplifications were the 
reason for BARHL1 overexpression on the mRNA level (Figure 10).  
A B 
BARHL1  BARHL1  
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Figure 10: Relative BARHL1 gene copy number in human medulloblastoma. Real-time 
PCR analysis was used to quantfiy the BARHL1 gene copy number in human 
medulloblastoma samples. Results were normalized to the B2M gene. The mean of 
relative BARHL1 gene copy number in adult cerebella was set 1. Amplification was 
defined as BARHL1 gene copy number > 5*mean of BARHL1 gene copy number in 
cerebellar tissue (see dotted line). None of the examined samples were amplified. CB, 
cerebellum; GBM, glioblastoma; MB, medulloblastoma.  
 
 
3.2. Barhl1 expression in Shh-induced mouse medulloblastoma an d its 
cerebellar precursor cells 
 
In order to further investigate the functional role of Barhl1 in tumor development, 
Math1-cre:SmoM2Fl/+ mice as a mouse model for Sonic hedgehog-associated 
medulloblastomas were used (Schüller et al., 2008). To characterize Barhl1 
expression during development and in Sonic hedgehog-driven mouse 
medulloblastomas, in situ hybridizations for Barhl1 on WT and Math1-
cre:SmoM2Fl/+ mice were performed. At postnatal day 7 (P7) Barhl1 was 
strongly expressed in cerebellar granule neurons (Figure 11A). Granule neuron 
precursors were labeled intensely throughout the external granule cell layer of 
the entire cerebellum, but Barhl1 expression was discontinuous in mature 
granule neurons of the internal granule cell layer (IGL). Barhl1 expression in the 
IGL was seen in cerebellar lobes II-V and X and to some extent in lobe VI, while 
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it was absent in lobes VII, VIII and IX (Figure 11A). In medulloblastomas from 
Math1-cre:SmoM2Fl/+ mice, Barhl1 expression was strongly present in the tumor 
tissue, and a weaker expression was seen in granule neurons of the internal 
granule cell layer (Figure 11B). To confirm these findings, real-time RT-PCR 
was used to quantify Barhl1 expression (Figure 11C). In agreement with the in 
situ experiments, Barhl1 expression levels were about 10 times higher during 
cerebellar development (P7) in comparison to adult cerebellum (P30), and high 
expression was found in medulloblastomas from Math1-cre:SmoM2Fl/+ mice. 
 
 
 
Figure 11: Barhl1 is strongly expressed in the granule cell lineage and in tumors from 
Math1-cre:SmoM2Fl/+ mice. (A) Sagittal sections from P7 wild type mice display strong 
expression of Barhl1 in cerebellar granule neurons. While granule neuron precursors 
are labeled throughout the EGL of the entire cerebellum, Barhl1 expression in mature 
granule neurons of the IGL is restricted to lobes II-V and X (see high power image with 
asterisk indicating Barhl1-negative granule neurons). (B) Sagittal cerebellar sections 
from Math1-cre:SmoM2Fl/+ mice. Top left: H&E staining of a characteristic 
medulloblastoma in a Math1-cre:SmoM2Fl/+ mouse. Top right: In situ hybridization for 
Barhl1 in the cerebellum of a Math1Cre:SmoM2Fl/+ mouse with strong expression in 
tumor tissue (lower left) and weak expression in IGL tissue (lower right). (C) Relative 
quantification of Barhl1 expression using real-time RT-PCR with results normalized to 
B2m. Barhl1 expression levels were significantly higher in cerebella on P7 and in 
medulloblastomas from Math1-cre:SmoM2Fl/+ (MS) mice as compared to adult 
cerebella (P30, p=0.002 and p=0.05 respectively). EGL, External granule cell layer; 
IGL, Internal granule cell layer; MB, Medulloblastoma. One asterisk: p≤0.05, two 
asterisks: p≤0.01. Scale bar is 1 mm and 100 µm for A, 1.5 mm for the H&E stain, 200 
µm for the Barhl1 low power and 50 µm for the Barhl1 high power images in B. 
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3.3. Barhl1 in vivo 
 
3.3.1. Deletion of Barhl1 in mouse medulloblastoma 
 
In order to investigate the functional role of Barhl1 for the development and 
progression of medulloblastoma, Barhl1+/-Math1-cre:SmoM2Fl/+ and Barhl1-/-
Math1-cre:SmoM2Fl/+ mice were generated. Similar to the previously described 
Math1-cre:SmoM2Fl/+ mice (Schüller et al., 2007), all generated Barhl1+/-Math1-
cre:SmoM2Fl/+ and Barhl1-/-Math1-cre:SmoM2Fl/+ mice developed 
medulloblastomas. As seen by H&E staining, all three genotypes displayed a 
similar morphology with tumors composed of small round blue tumor cells in 
high density (Figure 12A). While Barhl1 expression was strongly present in 
Math1-cre:SmoM2Fl/+ mice, Barhl1 levels were significantly decreased in 
Barhl1+/-Math1-cre:SmoM2Fl/+ mice (p=0.029) and were not detectable in  
Barhl1-/-Math1-cre:SmoM2Fl/+ mice (Figure 12B). To elucidate whether Barhl1 
expression in medulloblastoma has an impact on the survival of the mice, 
Kaplan-Meier curves of Math1-cre:SmoM2Fl/+ mice (n=51), Barhl1+/-Math1-
cre:SmoM2Fl/+ mice (n=46) and Barhl1-/-Math1-cre:SmoM2Fl/+ mice (n=12, 
Figure 12C) were established. Deletion of Barhl1 resulted in a significantly 
decreased survival of Barhl1+/-Math1-cre:SmoM2Fl/+ and Barhl1-/-Math1-
cre:SmoM2Fl/+ mice in comparison to Math1-cre:SmoM2Fl/+ mice (p=0.003 and 
p=0.002, respectively).  
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Figure 12:  Deletion of Barhl1 in Math1-cre:SmoM2Fl/+ mice. (A)  H&E staining of 
sagittal sections from medulloblastoma showed a similar morphology in Math1-
cre:SmoM2Fl/+, Barhl1+/-Math1-cre:SmoM2Fl/+ and Barhl1-/-Math1-cre:SmoM2Fl/+ mice. 
High magnifications revealed small round blue tumor cells in high density. (B) Barhl1 
expression was analyzed using real-time RT-PCR. Target gene level was normalized 
to B2m mRNA. Barhl1 levels were significantly decreased in Barhl1+/-Math1-
cre:SmoM2Fl/+ (B+/-MS) mice compared to Math1-cre:SmoM2Fl/+ (MS) mice (p=0.029) 
and were not detectable in Barhl1-/-Math1-cre:SmoM2Fl/+ (B-/-MS) mice. Hashmark 
indicates no detectable Barhl1 expression. Asterisk: p≤0.05 (C) Survival curves for 
Math1-cre:SmoM2Fl/+ (MS) mice (n=51), Barhl1+/-Math1-cre:SmoM2Fl/+ mice (Barhl1+/-
MS, n=46) and Barhl1-/-Math1-cre:SmoM2Fl/+ mice (Barhl1-/-MS n=12). Deletion of 
Barhl1 resulted in a significantly decreased survival of Barhl1+/-Math1-cre:SmoM2Fl/+ 
mice and Barhl1-/-Math1-cre:SmoM2Fl/+ mice in comparison to Math1-cre:SmoM2Fl/+ 
mice (p=0.003 and p=0.002 respectively). Scale bar is 1 mm for low power images and 
50 µm for high power images. 
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3.3.2. Immunohistochemical characterization of mous e medulloblastoma 
 
To find out why Barhl1 deletion resulted in a worse prognosis, Math1-
cre:SmoM2Fl/+, Barhl1+/-Math1-cre:SmoM2Fl/+ and Barhl1-/-Math1-cre:SmoM2Fl/+ 
mice were further analyzed by immunohistochemistry. As expected, Cre 
recombinase expression was strong in all three genotypes with a large majority 
of tumor cells being stained (Figure 14). NeuN, a marker for neuronal 
differentiation, is expressed in mature granule neurons of the internal granule 
cell layer (Weyer and Schilling, 2003), but also in medulloblastoma (Eberhart et 
al., 2001). Interestingly, Math1-cre:SmoM2Fl/+-derived medulloblastoma cells 
exhibited a strong expression of NeuN, but significantly fewer NeuN-positive 
cells were detectable in tumors from Barhl1+/-Math1-cre:SmoM2Fl/+ (p=0.004) 
and Barhl1-/-Math1-cre:SmoM2Fl/+ mice (p=0.012, Figure 13A). Similarly, 
expression of Zic, a marker for granule neuron differentiation and 
medulloblastoma (Yokota et al., 1996) was significantly reduced in Barhl1+/-
Math1-cre:SmoM2Fl/+ (p=0.034) and Barhl1-/-Math1-cre:SmoM2Fl/+ mice 
(p=0.016, Figure 13A). While Olig2 and Sox2, both of which label multipotent 
precursors (Schüller et al., 2008; Sutter et al. 2010), were found to be similarly 
expressed in all three genotypes (Figure 14), Synaptophysin and MAP2, as 
additional markers for neuronal differentiation, appeared to be more weakly 
expressed in Barhl1+/-Math1-cre:SmoM2Fl/+ and Barhl1-/-Math1-cre:SmoM2Fl/+ 
mice than in Math1-cre:SmoM2Fl/+ mice (Figure 14). In contrast, the percentage 
of phosphorylated Histone H3 (pHH3) positive tumor cells was significantly 
increased in Barhl1-/-Math1-cre:SmoM2Fl/+ mice in comparison to Barhl1+/-
Math1-cre:SmoM2Fl/+ mice (p=0.019) and Math1-cre:SmoM2fl/+ mice (p=0.012). 
Likewise, Barhl1+/-Math1-cre:SmoM2Fl/+ mice showed an elevated fraction of 
pHH3-positive tumor cells when compared to Math1-cre:SmoM2Fl/+ mice 
(p=0.045). Furthermore, Western Blot analysis showed that protein levels of 
cleaved caspase-3, a marker for apoptosis, were significantly reduced in  
Barhl1-/-Math1-cre:SmoM2Fl/+ mice when compared to Math1-cre:SmoM2Fl/+ 
mice (p=0.036, Figure 13B), and this may indicate some pro-apoptotic effect in 
medulloblastoma. Hence, medulloblastomas from Barhl1+/-Math1-cre:SmoM2Fl/+ 
and Barhl1-/-Math1-cre:SmoM2Fl/+ mice were characterized by a significantly 
decreased differentiation of tumor cells.  
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Figure 13: Immunohistochemical characterization of mouse medulloblastoma. 
(A) Immunostaining for NeuN, Zic and phosphorylated Histone H3 (pHH3). Scale bar is 
1mm for low power images and 50µm for high power images. Immunostaining for 
NeuN: Arrows point at strongly stained mature granule neurons in the internal granule 
cell layer (IGL). Strong NeuN expression was also found in tumor cells from Math1-
cre:SmoM2Fl/+ mice, but only marginal expression was seen in tumors from Barhl1+/-
Math1-cre:SmoM2Fl/+ and Barhl1-/-Math1-cre:SmoM2Fl/+ mice. The percentage of NeuN 
positive tumor cells was significantly reduced in Barhl1+/-Math1-cre:SmoM2Fl/+ (B+/-MS) 
mice (p=0.012) and Barhl1-/-Math1-cre:SmoM2Fl/+ (B-/-MS) mice (p=0.004) in 
comparison to Math1-cre:SmoM2Fl/+ (MS) mice. Immunostaining for Zic: The 
percentage of Zic positive tumor cells was significantly reduced in B+/-MS mice 
(p=0.034) and B-/-MS mice (p=0.016) compared to MS mice. Immunostaining for pHH3: 
The percentage of pHH3-positive tumor cells was significantly increased in B-/-MS mice 
in comparison to B+/-MS mice (p=0.019) and MS mice (p=0.012). B+/-MS mice showed 
increased pHH3-positive tumor cells when compared to MS mice (p=0.045).              
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(B) Western Blot for cleaved caspase-3. Protein levels of cleaved caspase-3 were 
significantly reduced in Barhl1-/-Math1-cre:SmoM2Fl/+ mice in comparison to Math1-
cre:SmoM2Fl/+ mice (p=0.036).  One asterisk: p≤0.05, two asterisks: p≤0.01. 
 
 
 
Figure 14:  Immunhistochemical characterization of mouse medulloblastoma. Strong 
Synaptophysin expression was found in tumor cells from Math1-cre:SmoM2Fl/+ mice, 
but only weak expression was seen in tumors from Barhl1+/- Math1-cre:SmoM2Fl/+ and  
Barhl1-/- Math1-cre:SmoM2Fl/+ mice. MAP2 displayed a similar pattern with robust 
staining in Math1-cre:SmoM2Fl/+ mice and weak staining in Barhl1+/- Math1-
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cre:SmoM2Fl/+ and  Barhl1-/- Math1-cre: SmoM2Fl/+ mice. Cre recombinase expression 
was strong in all three genotypes with the large majority of tumor cells being stained. 
Expression of Math1-cre, Olig2 and Sox2 was similar in all tumor genotypes. 
Differentiated cells of the normal cerebellum exhibited strong NSE staining, but all 
medulloblastomas (MB) were NSE negative. Scale bar is 50 µm for all images. 
 
 
3.4. BARHL1 expression in human medulloblastomas an d patients’ 
survival 
 
Having observed an important impact of Barhl1 on the differentiation and 
prognosis of murine medulloblastoma, the next intention was to analyze the 
survival of patients with respect to BARHL1 expression in human 
medulloblastoma. When separating the patients into two groups by using the 
median of relative BARHL1 expression in medulloblastoma, statistically 
significant differences in survival were not seen (data not shown). However, the 
13 patients exhibiting the highest relative BARHL1 expression values (high 
BARHL1) were found to have a significantly better prognosis than the rest of the 
group (low BARHL1, n=31, p=0.049, Figure 15). In particular, after 5 years of 
follow-up, none of the high BARHL1 cases had died, whereas the survival rate 
of patients with low BARHL1 medulloblastomas was only 0.59 (Figure 15).  
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Figure 15: Kaplan Meier analysis of patients with medulloblastoma that express high 
or low levels of BARHL1. The 13 patients exhibiting the highest relative BARHL1 
expression values (high BARHL1) were compared to the rest of the group (low 
BARHL1, n=31). High levels of BARHL1 were significantly correlated with a better 
prognosis (p=0.049). 
 
 
To validate the prognostic value of BARHL1 expression in a different set of 
medulloblastoma cases, the microarray expression data from an Amsterdam 
series of medulloblastoma patients were re-analyzed (Kool et al., 2008) and 
Kaplan Meier curves with respect to BARHL1 expression were established. To 
apply a similar threshold for BARHL1 expression, at first an expression cut-off 
at third quartile was used to divide the Amsterdam series in high and low 
BARHL1 cases. However, the 13 high BARHL1 cases only tended to have a 
better survival than the low BARHL1 cases, but statistical significance was not 
reached (n=36, p=0.357, Figure 16A).  Nevertheless, a significantly prolonged 
overall survival was found after splitting the series into 41 patients with high 
BARHL1 expression and 8 patients with low BARHL1 expression (p<0.001, 
Figure 16B).  
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Figure 16:  BARHL1 expression and survival in a different set of medulloblastoma 
cases (Kool et al., 2008). (A) Applying a similar threshold than in our patient group 
(expression cut-off at third quartile) shows a trend for favorable survival in the high 
BARHL1 group (n=13) when compared to the rest of the group (low BARHL1, n=36, 
p=0.357). (B) A significantly prolonged overall survival was found in the 41 patients 
showing high BARHL1 expression levels when compared to the remaining patients 
(low BARHL1, p<0.001). 
 
 
To see whether BARHL1 also correlated with differentiation markers in human 
medulloblastoma, again the microarray expression data of 62 medulloblastoma 
samples from the Amsterdam series were re-analyzed. Expression levels of 
NEUN and ZIC1 were significantly increased in the 50 medulloblastoma cases 
expressing BARHL1 when compared to the 12 medulloblastoma samples with 
no detectable BARHL1 expression (p=0.001 and p=0.021 respectively, see 
Figure 17A, B). Moreover, MAP2 expression levels were found to be 
significantly correlated with BARHL1 expression levels (p<0.001, data not 
shown). These findings suggest that the effects of BARHL1 were similar in 
mouse and human medulloblastoma, with loss or reduced BARHL1 expression 
being associated with decreased differentiation of the tumor cells and a worse 
prognosis of mice and patients.  
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Figure 17:  (A, B)  Expression of differentiation markers with respect to BARHL1 
expression in the set of medulloblastoma cases from Kool et al. 2008. Expression 
levels of NEUN and ZIC1 were significantly increased in the 50 medulloblastoma cases 
expressing BARHL1 when compared to the 12 medulloblastoma samples with no 
detectable BARHL1 expression (p=0.001 and p=0.021 respectively). One asterisk: 
p≤0.05, two asterisks: p≤0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 36 
4. Discussion 
 
Barhl1 is known to play a key role in cerebellar development having influence 
on migration and survival of granule neuron precursors (Li et al., 2004). I 
observed that Barhl1 expression was maintained in mature granule neurons of 
several anterior lobes of the cerebellum as well as in lobe X (Figure 11A). While 
expression of Barhl1 in mature granule neurons per se was confirmed by lacZ 
expression in Barhl1-/- mice (Li et al., 2004), the regional specificity of Barhl1 
expression in the cerebellum has not yet been functionally analyzed. 
Interestingly, this expression pattern correlates well with the expression of Gli1 
and En1 transcription factors, both of which are known to have crucial functions 
during cerebellar development (Millen et al., 1995; Corrales et al., 2004). While 
it is tempting to speculate on the functional role of Barhl1 itself with respect to 
anteroposterior pattering, it appears possible that Barhl1 functions in 
cooperation with the above mentioned genes.  
I further report that Barhl1 is expressed in medulloblastoma arising in Math1-
cre:SmoM2Fl/+ mice as well as in the majority of human medulloblastoma 
samples. Interestingly, loss of Barhl1 in Math1-cre:SmoM2Fl/+ derived 
medulloblastomas resulted in a down-regulation of neuronal differentiation 
markers, whereas mitotic activity of these cells was increased (Figure 13). 
Hence, apart from its role during normal cerebellar development, Barhl1 might 
play important roles for cell differentiation in medulloblastoma. Moreover, 
deletion of Barhl1 in Math1-cre:SmoM2Fl/+ mice led to a significantly decreased 
survival of these mice. Similarly, patients with low BARHL1 expression had a 
significantly worse prognosis and died earlier. The observation that loss of 
Barhl1 causes migration deficits in neurons of Barhl1 null mice (Li et al., 2004), 
extenuates the possibility that unfavorable survival of patients with 
medulloblastoma with low levels of Barhl1 expression might be due to 
enhanced migration or infiltration of medulloblastoma cells. I therefore suggest 
that the underlying mechanisms leading to a worse prognosis of patients and 
mice carrying tumors with low or no BARHL1 expression are mainly decreased 
differentiation and increased proliferation of medulloblastoma cells.  
A recent study found medulloblastoma to comprise 5 distinct molecular variants 
(Kool et al., 2008). Besides the SHH-associated tumors, the WNT group and 
three other, not yet well characterized groups have been described. While the 
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used mouse model highlights the role of Barhl1 in Shh-associated 
medulloblastomas, the functional impact of Barhl1 on tumors belonging to other 
molecular subgroups appears hard to investigate, mainly due to the lack of 
appropriate mouse models. Interestingly enough, of the 13 medulloblastoma 
samples exhibiting the highest BARHL1 expression values in our own series, 4 
samples showed a desmoplastic histology which is often associated with SHH-
associated medulloblastomas and one case carried a CTNNB1 mutation, a 
criterion for the WNT-associated variant (Kool et al., 2008). However, both 
desmoplastic histology and CTNNB1 mutations were also found in tumors with 
low BARHL1 expression. In line with this, expression of BARHL1 was similar in 
desmoplastic and in classic medulloblastomas (Figure 1C), suggesting an 
important role of Barhl1 for several, if not all medulloblastoma subtypes and 
indicating that the mechanisms revealed by Barhl1 loss in Math1-cre:SmoM2Fl/+ 
mice might be applied to all medulloblastoma subtypes.  
Barhl1 belongs to a family of homeodomain transcription factors which also 
includes the homologue Barhl2. Although these proteins are known to display 
distinct expression patterns in the nervous system, yet overlapping expression 
was found in granule neuron precursors of the cerebellum (Bulfone et al., 2000; 
Li et al., 2002; Mo et al., 2004). Moreover, Barhl1 and Barhl2 can transactivate 
the Barhl1 promoter (Chellappa et al., 2008). This could not only point towards 
a close interaction between Barhl1 and Barhl2 in granule neuron precursors but 
also to some compensating mechanisms in a Barhl1-null situation. However, I 
did not find any upregulation of Barhl2 expression in medulloblastomas from 
Barhl1+/-Math1-cre:SmoM2Fl/+ and Barhl1-/-Math1-cre:SmoM2Fl/+ mice. Neither 
was Barhl2 upregulated in Barhl1-/- and Barhl1+/- mice. Therefore, the function of 
Barhl2 in medulloblastoma pathology and normal granule cell development 
seems to be distinct from Barhl1 functions and effects of Barhl1 loss were 
neither mediated, nor extenuated by Barhl2. A statistically significant difference 
in survival with respect to BARHL1 expression was found in our group of 44 
patients. However, re-analysis of the microarray expression data from the 
Amsterdam series of medulloblastoma patients (Kool et al., 2008) did not 
confirm these results when using the same cutoff for BARHL1 expression as a 
prognostic indicator. This reinforces the fact that molecular markers relying on 
percentile rankings are not suitable for human clinical trials. Although BARHL1 
seems biologically important in medulloblastomas, its prognostic value still has 
 38 
to be defined, ideally prospectively in a large homogenously treated cohort of 
patients. 
Similar to Barhl1, several other genes are known to be associated with a 
favorable prognosis in medulloblastoma (Pomeroy et al., 2002). Among them, 
TRKC, the receptor for Neurotrophin-3 (NT-3), is well described (Segal et al., 
1994). Interestingly, its ligand, Nt-3, was suggested to be a major downstream 
gene of Barhl1 during cerebellar development (Li et al., 2004). Further 
understanding of the molecular interactions of BARHL1 and its partners will be 
promising to find specific therapeutic strategies for medulloblastoma treatment 
in the future. 
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5. Summary 
 
5.1. Summary 
 
Medulloblastoma is the most common malignant brain tumor in childhood, and 
development of targeted therapies is highly desired. While the molecular 
mechanisms of malignant transformation are not fully understood, it is known 
that medulloblastoma may arise from cerebellar granule neuron precursors. The 
homeodomain transcription factor Barhl1 is known to regulate migration and 
survival of granule cell precursors, but its functional role in medulloblastoma is 
unknown. It is shown here that expression of BARHL1 is significantly 
upregulated during human cerebellar development and in human 
medulloblastoma samples as compared to normal adult cerebellum. High levels 
of Barhl1 expression were detected in medulloblastomas of Math1-
cre:SmoM2Fl/+ mice, an established mouse model for Sonic hedgehog-
associated medulloblastomas. To investigate Barhl1 function in vivo during 
tumor development, Barhl1-/-Math1-cre:SmoM2Fl/+ and Barhl1+/-Math1-
cre:SmoM2Fl/+ mice were generated. Interestingly, tumors that developed in 
these mice displayed increased mitotic activity and decreased neuronal 
differentiation. Moreover, survival of these mice was significantly decreased. 
Similarly, low expression of BARHL1 in human medulloblastoma cases was 
associated with a less favorable prognosis for the patients. These results 
suggest that expression of Barhl1 decelerates tumor growth both in human and 
murine medulloblastoma and should be further investigated with respect to 
potential implications for individualized therapeutic strategies. 
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5.2. Zusammenfassung 
 
Das Medulloblastom ist der häufigste maligne Hirntumor des Kindesalters, und 
die Entwicklung von zielgerichteten, nebenwirkungsarmen Therapiestrategien 
hat oberste Priorität. Die molekularen Mechanismen der malignen 
Transformation dieses Tumors sind noch nicht bis ins Letzte verstanden, jedoch 
ist bekannt, dass Medulloblastome von Körnerzellvorläufern abstammen 
können.  Barhl1 ist einer der Transkriptionsfaktoren, die das Überleben und die 
Migration von Körnerzellvorläufern steuern, jedoch ist die Funktion, die Barhl1 
im Medulloblastom hat, noch unbekannt. Diese Arbeit zeigt, dass die 
Expression von  BARHL1 während der Entwicklungsphase des menschlichen 
Kleinhirns und in humanen Medulloblastomen im Vergleich zu Kleinhirnen von 
Erwachsenen signifikant hochreguliert ist. Hohe Barhl1 Expressionslevel 
wurden zudem in Medulloblastomen von Math1-cre:SmoM2Fl/+ Mäusen 
gefunden, welche ein bewährtes Mausmodel für Sonic hedgehog-assoziierte 
Medulloblastome darstellen, die von cerebellären Körnerzellvorläufern 
abstammen. Um die Funktion von Barhl1 in vivo während der Entwicklung und 
des Wachstums von Medulloblastomen zu untersuchen, wurden Barhl1-/- 
Math1-cre:SmoM2Fl/+ und Barhl1+/-Math1-cre:SmoM2Fl/+ Mäuse generiert. 
Interessanterweise zeigten Tumoren, die in diesen Mäusen entstanden, eine 
vermehrte mitotische Aktivität und eine verminderte neuronale Differenzierung. 
Zudem war das Überleben dieser Mäuse im Vergleich zu dem von Math1-
cre:SmoM2Fl/+ Mäusen signifikant verkürzt. Im Einklang mit diesen Ergebnissen 
zeigten Patienten, deren Medulloblastom eine niedrige BARHL1 Expression 
aufwies, eine schlechtere Prognose als Patienten, deren Tumoren eine höhere 
BARHL1 Expression aufwiesen. Diese Ergebnisse deuten darauf hin, dass die 
Expression von Barhl1 das Tumorwachstum in murinen und humanen 
Medulloblastomen verlangsamt. Deswegen sollte BARHL1 im Hinblick auf 
potentielle Anwendungen für individualisierte therapeutische Strategien weiter 
untersucht werden.  
 
 
 
 
 
 41 
6. References 
 
Alston RD, Newton R, Kelsey A, Newbould MJ, Birch JM, Lawson B, McNally RJ 
(2003). Childhood medulloblastoma in northwest Engla d 1954 to 1997: incidence and 
survival. Dev Med Child Neurol 45: 308-14. 
 
Bulfone A, Menguzzato E, Broccoli V, Marchitiello A, Gattuso C, Mariani M,  Consalez 
GG, Martinez S, Ballabio A, Banfi S (2000). Barhl1, a gene belonging to a new 
subfamily of mammalian homeobox genes, is expressed in migrating neurons of the 
CNS. Hum Mol Genet 9: 1443-52. 
 
Chellappa R, Li S, Pauley S, Jahan I, Jin K, Xiang M (2008). Barhl1 regulatory 
sequences required for cell-specific gene expression and autoregulation in the inner ear 
and central nervous system. Mol Cell Biol 28: 1905-14. 
 
Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R,  
Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ,  Gajjar A, 
Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, omeroy SL (2011). 
Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup 
That Drives Poor Clinical Outcome. J Clin Oncol. 29:1424-30 
 
Corrales JD, Rocco GL, Blaess S, Guo Q, Joyner AL (2004). Spatial pattern of sonic 
hedgehog signaling through Gli genes during cerebellum development. Development 
131: 5581-90. 
 
Crawford JR, MacDonald TJ, Packer RJ (2007). Medulloblastoma in childhood: new 
biological advances. Lancet Neurol 6: 1073-85. 
 
Eberhart CG, Kaufman WE, Tihan T, Burger PC (2001). Apoptosis, neuronal 
maturation, and neurotrophin expression within medulloblastoma nodules. J 
Neuropathol Exp Neurol 60: 462-9. 
 
Evans AE, Jenkin RD, Sposto R, Ortega JA, Wilson CB, Wara W, Ertel IJ, Kramer S, 
Chang CH, Leikin SL, Hammond GD (1990). The treatment of medulloblastoma. 
Results of a prospective randomized trial of radiation herapy with and without CCNU, 
vincristine, and prednisone. J Neurosurg 72: 572-82. 
 
Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA,  
Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z,  Scoggins 
M, Ogg R, Pei Y, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC,  Taketo MM, Boop 
FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF,  McKinnon PJ, Gutmann DH, 
Ellison DW, Wechsler-Reya R, Gilbertson RJ  (2010). Subtypes of medulloblastoma 
have distinct developmental origins. Nature 468: 1095-9. 
 
Gilbertson RJ (2004). Medulloblastoma: signalling a ch nge in treatment. Lancet Oncol 
5: 209-18. 
 
Gjerris F, Agerlin N, Borgesen SE, Buhl L, Haase J, Klinken L, Mortensen AC,  Olsen 
JH, Ovesen N, Reske-Nielsen E, Schmidt K (1998). Epidemiology and prognosis in 
children treated for intracranial tumours in Denmark 1960-1984. Childs Nerv Syst 14: 
302-11. 
 42 
 
Hartmann W, Koch A, Brune H, Waha A, Schüller U, Dani I, Denkhaus D, Langmann 
W, Bode U, Wiestler OD, Schilling K, Pietsch T  (2005). Insulin-like growth factor II is 
involved in the proliferation control of medulloblastoma and its cerebellar precursor 
cells. Am J Pathol 166: 1153-62. 
 
Heine VM, Rowitch DH (2009). Hedgehog signaling has  protective effect in 
glucocorticoid-induced mouse neonatal brain injury through an 11betaHSD2-dependent 
mechanism. J Clin Invest 119: 267-77. 
 
Hughes EN, Shillito J, Sallan SE, Loeffler JS, Cassady JR, Tarbell NJ (1988). 
Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The 
influence of radiation dose on the patterns of failure and survival. Cancer 61: 1992-8. 
 
Jeong J, Mao J, Tenzen T, Kottmann AH, McMahon AP (2004). Hedgehog signaling in 
the neural crest cells regulates the patterning and growth of facial primordia. Genes Dev 
18: 937-51. 
 
Kleihues P, Sobin LH (2000). World Health Organization classification of tumors. 
Cancer 88: 2887. 
 
Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, 
Caron HN, Cloos J, Mrsic A, Ylstra B, Grajkowska W,Hartmann W,  Pietsch T, Ellison 
D, Clifford SC, Versteeg R  (2008). Integrated genomics identifies five 
medulloblastoma subtypes with distinct genetic profiles, pathway signatures and 
clinicopathological features. PLoS One 3: e3088. 
 
Kortmann RD, Kuhl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E,  
Willich N, Flentje M, Berthold F, Slavc I, Wolff J, Meisner C, Wiestler O,  Sorensen N, 
Warmuth-Metz M, Bamberg M (2000). Postoperative neoadjuvant chemotherapy before 
radiotherapy as compared to immediate radiotherapy followed by maintenance 
chemotherapy in the treatment of medulloblastoma in ch ldhood: results of the German 
prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46: 269-79. 
 
Laughton SJ, Merchant TE, Sklar CA, Kun LE, Fouladi M, Broniscer A, Morris EB,  
Sanders RP, Krasin MJ, Shelso J, Xiong Z, Wallace D, Gajjar A (2008). Endocrine 
outcomes for children with embryonal brain tumors after risk-adapted craniospinal and 
conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue 
on the SJMB-96 trial. J Clin Oncol 26: 1112-8. 
 
Li S, Price SM, Cahill H, Ryugo DK, Shen MM, Xiang M (2002). Hearing loss caused 
by progressive degeneration of cochlear hair cells in mice deficient for the Barhl1 
homeobox gene. Development 129: 3523-32. 
 
Li S, Qiu F, Xu A, Price SM, Xiang M (2004). Barhl1 regulates migration and survival 
of cerebellar granule cells by controlling expression of the neurotrophin-3 gene. J 
Neurosci 24: 3104-14. 
 
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer 
BW, Kleihues P (2007). The 2007 WHO classification of tumours of the central nervous 
system. Acta Neuropathol 114: 97-109. 
 
 43 
Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D, McMahon AP  
(2006). A novel somatic mouse model to survey tumorigenic potential applied to the 
Hedgehog pathway. Cancer Res 66: 10171-8. 
 
Matei V, Pauley S, Kaing S, Rowitch D, Beisel KW, Morris K, Feng F, Jones K,  Lee J, 
Fritzsch B (2005). Smaller inner ear sensory epithelia in Neurog 1 null mice are related 
to earlier hair cell cycle exit. Dev Dyn 234: 633-50. 
 
Millen KJ, Hui CC, Joyner AL (1995). A role for En-2 and other murine homologues of 
Drosophila segment polarity genes in regulating positional information in the 
developing cerebellum. Development 121: 3935-45. 
 
Mo Z, Li S, Yang X, Xiang M (2004). Role of the Barhl2 homeobox gene in the 
specification of glycinergic amacrine cells. Development 131: 1607-18. 
 
Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E,  
Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD (2011). 
Medulloblastoma Comprises Four Distinct Molecular Viants. J Clin Oncol. 29: 1408-
14 
 
Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L,  
LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R  (2006). 
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for 
newly diagnosed average-risk medulloblastoma. J Clin Oncol 24: 4202-8. 
 
Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim 
JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, 
Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A,  Stolovitzky G, 
Louis DN, Mesirov JP, Lander ES, Golub TR (2002). Prediction of central nervous 
system embryonal tumour outcome based on gene expression. Nature 415: 436-42. 
 
Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJ, van Zandwijk N, 
Schellens JH (2006). Relationship between cisplatin administration and the 
development of ototoxicity. J Clin Oncol 24: 918-24. 
 
Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM (2001). Intellectual 
outcome after reduced-dose radiation therapy plus adjuv nt chemotherapy for 
medulloblastoma: a Children's Cancer Group study. J Clin Oncol 19: 3470-6. 
 
Scales SJ, de Sauvage FJ (2009). Mechanisms of Hedgehog pathway activation in 
cancer and implications for therapy. Trends Pharmacol Sci 30: 303-12. 
 
Schüller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, Huillard E, Sun T,  Ligon 
AH, Qian Y, Ma Q, Alvarez-Buylla A, McMahon AP, Rowitch DH, Ligon KL  (2008). 
Acquisition of granule neuron precursor identity is a critical determinant of progenitor 
cell competence to form Shh-induced medulloblastoma. Cancer Cell 14: 123-34. 
 
Schüller U, Zhao Q, Godinho SA, Heine VM, Medema RH, Pellman D, Rowitch DH  
(2007). Forkhead transcription factor FoxM1 regulates mitotic entry and prevents 
spindle defects in cerebellar granule neuron precursors. Mol Cell Biol 27: 8259-70. 
 
 44 
Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL (1994). Expression of 
the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. 
Proc Natl Acad Sci U S A 91: 12867-71. 
 
Soriano P (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. 
Nat Genet 21: 70-1. 
 
Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, Costantini F  
(2001). Cre reporter strains produced by targeted insertion of EYFP and ECFP into the 
ROSA26 locus. BMC Dev Biol 1: 4. 
 
Sutter R, Shakhova O, Bhagat H, Behesti H, Sutter C, Penkar S, Santuccione A,  
Bernays R, Heppner FL, Schüller U, Grotzer M, Moch H, Schraml P, Marino S  (2010). 
Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a 
neural stem cell signature characterizes a subset of human medulloblastomas. Oncogene 
29: 1845-56. 
 
Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P (1990). Adjuvant 
chemotherapy for medulloblastoma: the first multi-centre control trial of the 
International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26: 464-9. 
 
Tarbell NJ, Loeffler JS, Silver B, Lynch E, Lavally BL, Kupsky WJ, Scott RM, Sallan 
SE  (1991). The change in patterns of relapse in medulloblastoma. Cancer 68: 1600-4. 
 
Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H,  
Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS (2003). Results of 
a randomized study of preradiation chemotherapy versus radiotherapy alone for 
nonmetastatic medulloblastoma: The International Society of Paediatric 
Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 
21: 1581-91. 
 
Thorne RN, Pearson AD, Nicoll JA, Coakham HB, Oakhill A, Mott MG, Foreman NK 
(1994). Decline in incidence of medulloblastoma in children. Cancer 74: 3240-4. 
 
Weyer A, Schilling K (2003). Developmental and cell type-specific expression of the 
neuronal marker NeuN in the murine cerebellum. J Neurosci Res 73: 400-9. 
 
Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, Bonifas JM, Lam CW, Hynes M, 
Goddard A, Rosenthal A, Epstein EH, de Sauvage FJ (1998). Activating Smoothened 
mutations in sporadic basal-cell carcinoma. N ture 391: 90-2. 
 
Xu W, Janss A, Packer RJ, Phillips P, Goldwein J, Moshang T, Jr. (2004). Endocrine 
outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation 
therapy. Neuro Oncol 6: 113-8. 
 
Yokota N, Aruga J, Takai S, Yamada K, Hamazaki M, Iwase T, Sugimura H,  Mikoshiba 
K (1996). Predominant expression of human zic in cerebellar granule cell lineage and 
medulloblastoma. Cancer Res 56: 377-83. 
 
 
 
 
 45 
7. Acknowledgements 
 
Special thanks go to my supervisor PD Dr. med. Ulrich Schüller for giving me 
the opportunity to work on this interesting topic, for always taking the time to 
answer my questions, for his exceptional support and for a lot of fruitful and 
motivating discussions. Moreover, I like to thank the director of the Zentrum für 
Neuropathologie und Prionforschung, Prof. Dr. med. Dr. h. c. Hans 
Kretzschmar, for giving me the possibility to do my work at this institution. I am 
indebted to Michael Schmidt, Veronika Kaltenbrunn, Dagmar Metzger, Philipp 
Neumann, and Silvia Occhionero for excellent technical support and to Dr. 
Mehdi Shakarami and Dr. Stefanie Ohlemeyer for animal husbandry. I 
acknowledge Prof. Dr. Rosalind Segal for providing Zic antibodies and Dr. 
Shengguo Li and Prof. Dr. Mengqing Xiang for providing the Barhl1-/- mice. I 
refer to Dr. Andreas Lorenz, PD Dr. Aurelia Peraud, Dr. André von Bueren, 
Prof. Dr. Jörg-Christian Tonn, Prof. Dr. Stefan Rutkowski and Prof. Dr. Jochen 
Herms for providing human tumor samples and clinical information. I thank PD 
Dr. Wolfgang Hartmann for help with the Western blot and Dr. Marcel Kool for 
providing his data for re-analysis. Additionally, I want to thank the Kind-Philipp-
Stiftung für Leukämieforschung for financial support when presenting my results 
at the XVIIth International Congress of Neuropathology.   
 
 
 
 
